NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee D meeting minutes

**Minutes:** Confirmed

**Date and time:** Thursday 16 September 2021

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Megan John (Topic 1 Chair) Present for all items
2. Dr Lindsay Smith (Topic 2 Chair) Present for all items
3. Dr Paul Arundel (Topic 3 Chair) Items 6 to 6.2.2
4. Martin Bradley Items 1 to 5.2.2
5. Professor Sofia Dias Present for all items
6. Professor Rachel Elliott Present for all items
7. Professor Paula Ghaneh Present for all items
8. Chris Herring Present for all items
9. Dr Andrew Hitchings Items 1 to 5.2.2
10. Dr Robert Hodgson Present for all items
11. Dr Bernard Khoo Present for all items
12. Ivan Koychev Present for all items
13. Dr Guy Makin Present for all items
14. Giles Monnickendam Present for all items
15. Malcolm Oswald Present for all items
16. Dr Rebecca Payne Present for all items
17. Professor Chris Parker Items 1 to 5.2.2
18. Baljit Singh Present for all items
19. Dr Ed Wilson Present for all items

NICE staff present

Linda Landells, Associate Director Items 1 to 4.2.2 & 6 to 6.2.2

Ross Dent, Associate Director Items 5 to 5.2.2

Kate Moore, Project Manager Items 1 to 4.2.2 & 6 to 6.2.2

Louise Jafferally, Project Manager Items 1 to 5.2.2

Hannah Nicholas, Health Technology Assessment Adviser Items 1 to 4.2.2

Caron Jones, Health Technology Assessment Adviser Items 5 to 5.2.2

Christian Griffiths, Health Technology Assessment Adviser Items 6 to 6.2.2

Anita Sanga, Health Technology Assessment Adviser Items 1 to 4.2.2

Laura Coote, Health Technology Assessment Analyst Items 5 to 5.2.2

Sam Harper, Health Technology Assessment Analyst Items 5 to 5.2.2

Amy Crossley, Health Technology Assessment Analyst Items 6 to 6.2.2

George J. Millington, Health Technology Assessment Analyst Items 6 to 6.2.2

Catrin Austin, Technical Analyst, Centre for Guidelines Items 5 to 5.2.2

Emily Eaton Turner, Technical Adviser, Commercial Risk Assessment Items 2 to 5.2.2

Claire Hawksworth, Technical Analyst, Evidence Generation Items 5 to 5.2.2

Ella Livingstone, Technical Adviser, Commercial Risk Assessment Items 6 to 6.2.2

Stevie Okoro, Technical Analyst, Commercial Risk Assessment Items 6 to 6.2.2

Cara Gibbons, Assistant Health Technology Assessment Analyst Items 1 to 4.1.3 & 5 to 5.2.2

Nicola Bodey, Senior Business Analyst, RIA Items 1 to 4.2.2 & 6 to 6.1.3

Korin Knight, Senior Medical Editor Items 1 to 4.2.2

Hayley Garnett, Senior Medical Editor Items 5 to 6.2.2

Mandy Tonkinson, Public Involvement Adviser Items 1 to 4.1.3 & 5 to 5.1.3

James Devine, Coordinator, COT Items 1 to 5.1.3

Lucinda Evans, Coordinator, MIP, Items 1 to 4.1.3, 5 to 5.1.3 & 6 to 6.1.3

Gemma Smith, Coordinator, COT Present for all items

Iain Cannell, Administrator, TA Items 5 to 5.2.2

Celia Mayers, Administrator, TA Items 1 to 4.2.2 & 6 to 6.2.2

Daniel Greenwood, Assistant Administrator, COT Items 6 to 6.2.2

External review group representatives present

Nigel Armstrong, Kleijnen Systematic Reviews Ltd Items 1 to 4.1.3

Sabine Grimm, Kleijnen Systematic Reviews Ltd Items 1 to 4.1.3

Katy Cooper, School of Health and Related Research (ScHARR) Items 5 to 5.1.3

Paul Tappenden, School of Health and Related Research (ScHARR) Items 5 to 5.1.3

Rob Riemsma, Kleijnen Systematic Reviews Ltd Items 6 to 6.2.2

Hannah Penton, Kleijnen Systematic Reviews Ltd Items 6 to 6.2.2

Experts present

Professor Chris Edwards, Consultant Rheumatologist, clinical expert nominated by GSK, Present for items 1 to 4.1.3

Dr Peter Lanyon, Consultant Rheumatologist, clinical expert nominated by NHS England Specialised Rheumatology Clinical Reference Group, Present for items 1 to 4.1.3

Abbie Thomas, Patient expert nominated by Lupus UK, Present for items 1 to 4.1.3

Professor Peter Clark, National Clinical lead for Cancer drugs, NHS England, Present for items 5 to 5.2.2

Jenny Abbott, Patient expert nominated by EGFR Positive UK, Items 5 to 5.1.3

Professor Eric Lim, Professor of Thoracic Surgery, clinical expert nominated by AstraZeneca UK Ltd, Items 5 to 5.1.3

Dr Andrew Robinson, Consultant Pathologist, clinical expert nominated by The Royal College of Pathologists, Items 5 to 5.1.3

## Minutes

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted committee member apologies.

### News and announcements

* 1. None

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Thursday 12 August 2021.

### Appraisal of belimumab for the treatment of active autoantibody-positive systemic lupus erythematosus - Review of TA397 [ID1591]

* 1. Part 1 – Open session
		1. The chair Dr Megan John welcomed the invited clinical and patient experts, external review group representatives, members of the public and company representatives from GlaxoSmithKline.
		2. The chair asked all committee members, clinical and patient experts, external review group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Ivan Koychev declared financial interests as in the past he has worked on a project developing digital technologies for monitoring cognition funded and done in collaboration with Roche.
* It was agreed that his declaration would not prevent Ivan from participating in this section of the meeting.
* Committee member Dr Ed Wilson declared financial interests as Pfizer and Roche are clients of his company, but they have not worked on cyclophosphamide or rituximab (MabThera).
* It was agreed that his declaration would not prevent Dr Wilson from participating in this section of the meeting.
* Nominated clinical expert Professor Chris Edwards declared financial and professional interests as he has received honoraria for attending advisory boards and speaking events from GSK & Roche. He is an author on publications related to the BILAG biologics registry in the UK and a member of the BILAG group.
* It was agreed that his declaration would not prevent Professor Edwards from providing expert advice to the committee.
* Nominated clinical expert Dr Peter Lanyon declared financial and non-financial professional interests as he is in receipt of a research grant (co-applicant) from Vifor Pharma to the University of Nottingham. Vifor Pharma have no influence on the design, conduct or interpretation of the research, which is not related to either lupus or belimumab. He is the National Clinical Co-Lead for Rheumatology, Getting It Right First Time (GIRFT) Programme, NHS England and NHS Improvement, the Clinical Lead, National Congenital Anomaly and Rare Disease Registration Service (NCARDRS), Public Health England, Co-chair, Rare Autoimmune Rheumatic Disease Alliance (RAIRDA) – whose membership includes LUPUS UK and he is Co-author of research publications on lupus including epidemiology (prevalence and outcome) and multicentre clinical audit (compliance with BSR guideline for the management of systemic lupus erythematosus in adults)
* It was agreed that his declaration would not prevent Dr Lanyon from providing expert advice to the committee.
* No further conflicts were declared for this item,
	+ 1. The Chair led a discussion of the consultation comments presented to the committee.
	1. Part 2– Closed session (company representatives, clinical and patient experts, external group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Document (FAD). The committee decision was reached by consensus..
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Document (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10626>

### Appraisal of osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection [ID3835]

* 1. Part 1 – Open session
		1. The chair Dr Lindsay Smith welcomed the invited clinical and patient experts, National Clinical lead for cancer drugs fund, external review group representatives, members of the public and company representatives from AstraZeneca.
		2. The chair asked all committee members, clinical and patient experts, National Clinical lead for cancer drugs fund, external review group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Dr Ivan Koychev declared professional interests as he was recently awarded an NIHR fellowship which will be done in collaboration with AstraZeneca. The work will focus on non-oncological compounds for the treatment of Alzheimer's disease
* It was agreed that his declaration would not prevent Dr Koychev from participating in this section of the meeting.
* Committee Member Dr Ed Wilson declared financial interests as AstraZeneca are clients of his company, but they have not worked on osimertinib.
* It was agreed that his declaration would not prevent Dr Wilson from participating in this section of the meeting.
* Nominated clinical expert Professor Eric Lim declared financial interests as he has received personal fees from AstraZeneca for advisory board, education meetings and grants and personal fees from Abbott Molecular, Glaxo Smith Kline, Pfizer, Novartis, Medtronic / Covidien, Roche, Lily Oncology, Boehringer Ingelheim, Medela, ScreenCell, Johnson and Johnson / Ethicon, Clearbridge Biomedics, Illumina, Guardant Health, and BMS. He also has a patent P57988GB issued to Imperial Innovations relating to blood-based EGFR testing.
* It was agreed that his declaration would not prevent Dr Lim from providing expert advice to the committee.
* Nominated clinical expert Dr Andrew Robinson declared financial interests as he has received payment from AstraZeneca for speaking engagement regarding impacts of COVID in histopathology in November 2020. Dr Robinson also declared that he is also due to receive honorarium for giving a presentation on June 30, 2021.
* It was agreed that his declaration would not prevent Dr Robinson from providing expert advice to the committee.
* No further conflicts were declared for this item.
	+ 1. The Chair led a discussion of the consultation comments presented to the committee.
	1. Part 2 – Closed session (company representatives, clinical and patient experts, external review group representatives and members of the public were asked to leave the meeting).
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Document (FAD). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Document (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10756>

### Appraisal of mexiletine for treating myotonia in adults with non-dystrophic myotonic disorders [ID1488]

* 1. Part 1 – Open session
		1. The chair Dr Paul Arundel welcomed the external review group representatives, members of the public and company representatives from Lupin Pharmaceuticals
		2. The chair asked all committee members, external review group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee Member Dr Ed Wilson declared financial interests as Lupin are clients of his company, but they have not worked on mexiletine.
* It was agreed that his declaration would not prevent Dr Wilson from participating in this section of the meeting
* No further conflicts were declared for this item.
	+ 1. The Chair led a discussion of the consultation comments presented to the committee.
	1. Part 2 – Closed session (company representatives, external review group representatives and members of the public were asked to leave the meeting).
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Document (FAD). The committee decision was reached by consensus..
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Document (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10432>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee D will be held on Thursday 14 October 2021 and will start promptly at 9.30am.